Companies › Precision Biologics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NEO-201 | – | Phase 1 | Non Small Cell Lung Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03476681 | NEO-201 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Nov 2026 |
Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $54m a year; runway about 18 months at that burn, to Apr 2028
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.